Arylsubstituerede aminderivater, der er anvendelige ved cancerterapi

Use of compounds of formula (I) wherein A represents a group selected from: X represents -CH- or -N-; R represents a hydrogen or halogen atom, a C1-4 alkoxy group, a C1-4 alkyl group, or a C1-4 alkyl group substituted by 1 to 3 halogen atoms; R represents a hydrogen or halogen atom, a C1-4 alkoxy group, benzyloxy or a group -R COOR (wherein R represents a single bond or a C1-7 bivalent aliphatic hydrocarbon group and R represents a hydrogen atom or a C1-4 alkyl group) or a group R CONR R (wherein R and R each represent a hydrogen atom or a C1-4 alkyl group, or together with the nitrogen atom to which they are attached form a 4-6 membered saturated heterocyclic ring); R and R , which may be the same or different each represent a hydrogen atom or a C1-4 alkyl group, or R and R together with the nitrogen atom to which they are attached form a 4-6 membered saturated heterocyclic ring, which may optionally contain an oxygen atom or a further nitrogen atom, which may itself be substituted by a C1-4 alkyl group; R and R each represent a hydrogen atom or together form a linking group between the aromatic rings, said group being selected from -CH2CH2-, -CH2O-, -OCH2-, -NHCH2, or -CH2NH; n is zero or an integer from 1 to 3; and p and q are each independently an integer from 1 to 4, with the provisos that (a) when R and R form a linking group, A is not -CH2 @-(CH2)n- and (b) when A represents a group @ @C=CH(CH2)n- and n is 1, R is methyl, NR R is pyrrolidino and R and R are both hydrogen then R is not hydrogen or -CH=CHCO2H, and pharmaceutically acceptable salts thereof in the manufacture of a medicament for enhancing the therapeutic effect of an antineoplastic agent.